INVENTIVA SA (6IV.DE) Fundamental Analysis & Valuation

FRA:6IV • FR0013233012

Current stock price

5.27 EUR
-0.05 (-0.94%)
Last:

This 6IV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. 6IV.DE Profitability Analysis

1.1 Basic Checks

  • 6IV had negative earnings in the past year.
  • 6IV had a negative operating cash flow in the past year.
  • 6IV had negative earnings in each of the past 5 years.
  • 6IV had a negative operating cash flow in each of the past 5 years.
6IV.DE Yearly Net Income VS EBIT VS OCF VS FCF6IV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of 6IV (-173.72%) is worse than 85.54% of its industry peers.
Industry RankSector Rank
ROA -173.72%
ROE N/A
ROIC N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
6IV.DE Yearly ROA, ROE, ROIC6IV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for 6IV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
6IV.DE Yearly Profit, Operating, Gross Margins6IV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. 6IV.DE Health Analysis

2.1 Basic Checks

  • 6IV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 6IV has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 6IV has been increased compared to 5 years ago.
  • Compared to 1 year ago, 6IV has an improved debt to assets ratio.
6IV.DE Yearly Shares Outstanding6IV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
6IV.DE Yearly Total Debt VS Total Assets6IV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -0.33, we must say that 6IV is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.33, 6IV perfoms like the industry average, outperforming 44.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.33
ROIC/WACCN/A
WACC7.98%
6IV.DE Yearly LT Debt VS Equity VS FCF6IV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 2.96 indicates that 6IV has no problem at all paying its short term obligations.
  • 6IV has a better Current ratio (2.96) than 61.45% of its industry peers.
  • 6IV has a Quick Ratio of 2.96. This indicates that 6IV is financially healthy and has no problem in meeting its short term obligations.
  • 6IV has a Quick ratio of 2.96. This is in the better half of the industry: 6IV outperforms 66.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
6IV.DE Yearly Current Assets VS Current Liabilites6IV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 6IV.DE Growth Analysis

3.1 Past

  • 6IV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.11%.
  • Looking at the last year, 6IV shows a very negative growth in Revenue. The Revenue has decreased by -12.84% in the last year.
  • Measured over the past years, 6IV shows a small growth in Revenue. The Revenue has been growing by 5.62% on average per year.
EPS 1Y (TTM)-74.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

  • Based on estimates for the next years, 6IV will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.43% on average per year.
  • The Revenue is expected to grow by 110.44% on average over the next years. This is a very strong growth
EPS Next Y42.42%
EPS Next 2Y25.63%
EPS Next 3Y14.98%
EPS Next 5Y13.43%
Revenue Next Year6.05%
Revenue Next 2Y-47.41%
Revenue Next 3Y47.58%
Revenue Next 5Y110.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
6IV.DE Yearly Revenue VS Estimates6IV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
6IV.DE Yearly EPS VS Estimates6IV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. 6IV.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 6IV. In the last year negative earnings were reported.
  • Also next year 6IV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
6IV.DE Price Earnings VS Forward Price Earnings6IV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
6IV.DE Per share data6IV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as 6IV's earnings are expected to grow with 14.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.63%
EPS Next 3Y14.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 6IV.DE Dividend Analysis

5.1 Amount

  • 6IV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

6IV.DE Fundamentals: All Metrics, Ratios and Statistics

INVENTIVA SA

FRA:6IV (3/13/2026, 7:00:00 PM)

5.27

-0.05 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21
Earnings (Next)03-30
Inst Owners37.6%
Inst Owner ChangeN/A
Ins Owners4.6%
Ins Owner ChangeN/A
Market Cap1.09B
Revenue(TTM)13.61M
Net Income(TTM)-310.88M
Analysts88
Price Target13.46 (155.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-5.18%
EPS NY rev (3m)-2.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)4.11%
Revenue NY rev (3m)24.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 79.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.07
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.71%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -0.33
F-Score4
WACC7.98%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
EPS Next Y42.42%
EPS Next 2Y25.63%
EPS Next 3Y14.98%
EPS Next 5Y13.43%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year6.05%
Revenue Next 2Y-47.41%
Revenue Next 3Y47.58%
Revenue Next 5Y110.44%
EBIT growth 1Y10.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.23%
EBIT Next 3Y3.61%
EBIT Next 5Y13.47%
FCF growth 1Y-42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.45%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / 6IV.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INVENTIVA SA?

ChartMill assigns a fundamental rating of 2 / 10 to 6IV.DE.


What is the valuation status of INVENTIVA SA (6IV.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (6IV.DE). This can be considered as Overvalued.


What is the profitability of 6IV stock?

INVENTIVA SA (6IV.DE) has a profitability rating of 0 / 10.


How financially healthy is INVENTIVA SA?

The financial health rating of INVENTIVA SA (6IV.DE) is 3 / 10.